Please login to the form below

Not currently logged in

Merck and MacroGenics collaborate on immuno-oncology

Evaluates margetuximab with Keytruda for gastric cancer

Merck & Co. have agreed to collaborate with MacroGenics to evaluate the combination of margetuximab with Keytruda in patients with advanced gastric cancer.

The collaboration will consist of two trials - the first phase I trial to determine the safety and tolerability of the combination, and a second phase II trial to evaluate the anti-tumour effect of the drugs.

Dr Eric Rubin, VP and therapeutic area head of oncology early-stage development at Merck, said: “Today, there is a great opportunity and need to bring forward new scientific breakthroughs for the treatment of gastric cancer.

“Evaluating the potential of combination therapies through strategic collaborations in difficult-to-treat tumor types continues to be an important part of our immune-oncology clinical development program for Keytruda.”

Trial start-up activities are already underway with the first patients expected to be enrolled in the first quarter of 2016.

Margetuximab is an Fc-optimised monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2 - an antigen critical for the growth of a variety of tumours including breast and gastroesophageal cancers.

Macrogenics also began a collaboration with Takeda in October last year to develop and commercialise as many as four drugs with the potential of making $400m.

Keytruda was recently granted accelerated approval by the FDA to treat patients with advance non-small cell lung cancer and tumours that express PD-L1.

Though Keytruda faces stiff competition from BMS' Opdivo, analysts expect 2020 sales of Keytruda in the range of $5bn. 

Article by
Nikhil Patel

29th October 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...